Here are the 10-K annual reports from PROCEPT BioRobotics Corporation (PRCT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PRCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRCT filings page.
PROCEPT BioRobotics Corporation filed its annual report detailing its surgical robotics business focused on treating benign prostatic hyperplasia (BPH) with its AquaBeam and HYDROS robotic systems. Revenue grew to $308.1 million in 2025 from $224.5 million in 2024, while net loss was $95.6 million, with an accumulated deficit of $641.6 million.
As of December 31, 2025, the company had an installed base of 912 systems globally, including 718 in the United States. Management cites an estimated $30 billion U.S. addressable market for Aquablation therapy and highlights broad reimbursement coverage that it estimates reaches about 95% of U.S. men.
The report emphasizes extensive clinical data supporting Aquablation therapy, growing international presence, ongoing prostate cancer clinical trials, and continued investment in R&D, AI-enabled features, and sales and marketing to expand system placements and procedure volumes.